KALA BIO (KALA) Competitors $7.45 -0.05 (-0.67%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$7.42 -0.04 (-0.47%) As of 08/4/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. OGI, TVGN, CYBN, DMAC, CRDF, RAPT, CTOR, DERM, ACRS, and LYELShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Organigram Global (OGI), Semper Paratus Acquisition (TVGN), Cybin (CYBN), DiaMedica Therapeutics (DMAC), Cardiff Oncology (CRDF), Rapt Therapeutics (RAPT), Citius Oncology (CTOR), Journey Medical (DERM), Aclaris Therapeutics (ACRS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors Organigram Global Semper Paratus Acquisition Cybin DiaMedica Therapeutics Cardiff Oncology Rapt Therapeutics Citius Oncology Journey Medical Aclaris Therapeutics Lyell Immunopharma Organigram Global (NASDAQ:OGI) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Is OGI or KALA more profitable? Organigram Global has a net margin of 8.05% compared to KALA BIO's net margin of 0.00%. Organigram Global's return on equity of -5.93% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Organigram Global8.05% -5.93% -4.39% KALA BIO N/A -369.29%-64.99% Which has more volatility & risk, OGI or KALA? Organigram Global has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.81, meaning that its stock price is 281% less volatile than the S&P 500. Do analysts recommend OGI or KALA? KALA BIO has a consensus price target of $13.00, indicating a potential upside of 74.50%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in OGI or KALA? 34.6% of Organigram Global shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 8.3% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, OGI or KALA? Organigram Global has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram Global$117.47M1.57-$33.39M$0.1013.80KALA BIO$3.89M12.35-$38.51M-$8.24-0.90 Does the media favor OGI or KALA? In the previous week, Organigram Global had 2 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Organigram Global and 1 mentions for KALA BIO. Organigram Global's average media sentiment score of 0.40 beat KALA BIO's score of 0.00 indicating that Organigram Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram Global 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOrganigram Global beats KALA BIO on 11 of the 16 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.39M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.15%P/E Ratio-0.9018.0629.1424.41Price / Sales12.35272.71435.00101.03Price / CashN/A40.5624.4827.20Price / Book3.698.628.525.77Net Income-$38.51M-$54.98M$3.24B$264.99M7 Day Performance-11.31%-0.87%0.65%-0.68%1 Month Performance40.83%16.08%7.97%7.08%1 Year Performance29.34%14.18%30.98%23.80% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.5253 of 5 stars$7.45-0.7%$13.00+74.5%+26.3%$48.39M$3.89M-0.9030OGIOrganigram Global1.2691 of 5 stars$1.35+0.4%N/A-7.4%$180.27M$194.09M13.45860TVGNSemper Paratus Acquisition3.5147 of 5 stars$0.98-0.9%$10.00+920.4%+76.9%$180.22MN/A0.003Analyst ForecastCYBNCybin2.859 of 5 stars$7.65-0.6%$85.00+1,011.8%N/A$179.28MN/A-1.7350News CoverageGap DownDMACDiaMedica Therapeutics1.2241 of 5 stars$4.11-2.7%$10.75+161.9%+31.7%$176.02MN/A-6.4120Positive NewsUpcoming EarningsCRDFCardiff Oncology1.9498 of 5 stars$2.67+12.8%$11.70+337.7%+12.1%$175.96M$545K-3.0420Earnings ReportHigh Trading VolumeRAPTRapt Therapeutics4.0175 of 5 stars$10.36-4.1%$20.57+98.6%-54.6%$171.31MN/A-0.5480Upcoming EarningsCTORCitius Oncology0.9701 of 5 stars$2.19-1.1%$3.00+37.3%N/A$171.24MN/A0.00N/ADERMJourney Medical1.9779 of 5 stars$7.23-1.6%$9.50+31.3%+36.5%$168.53M$56.13M-18.5590News CoverageUpcoming EarningsACRSAclaris Therapeutics2.005 of 5 stars$1.56+1.6%$8.71+460.4%+21.9%$168.38M$18.72M-1.12100Upcoming EarningsLYELLyell Immunopharma2.9662 of 5 stars$11.36-3.8%$15.00+32.0%-61.8%$168.24M$60K-0.45270Upcoming Earnings Related Companies and Tools Related Companies Organigram Global Competitors Semper Paratus Acquisition Competitors Cybin Competitors DiaMedica Therapeutics Competitors Cardiff Oncology Competitors Rapt Therapeutics Competitors Citius Oncology Competitors Journey Medical Competitors Aclaris Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts